Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline And University Of Nottingham Establish Research Center

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:46am CEST

Drug maker GlaxoSmithKline PLC (>> GlaxoSmithKline plc) and the University of Nottingham said Thursday that they formalized a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.

MAIN FACTS:

-The Laboratory for Sustainable Chemistry is being supported by a GBP12 million grant from Glaxo.

-Shares at 0829 GMT, down 10 pence, or 0.71%, at 1,403.5 pence valuing the company at GBP71.28 million.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
04/21 GLAXOSMITHKLINE : $3 million awarded to widow who sued pharmaceutical firm over ..
04/21 TEVA PHARMACEUTICAL INDUSTRIES LTD ( : TEVA) Asthma Inhaler To Compete With Glax..
04/21 GLAXOSMITHKLINE : $3M award in suit against drug company over man's suicide
04/21 GLAXOSMITHKLINE : Widow who sued pharmaceutical firm over husband's suicide awar..
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/20 GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Update Current Data on Pharma..
04/20 GLAXOSMITHKLINE : Researchers from GlaxoSmithKline plc Detail New Studies and Fi..
04/20 GLAXOSMITHKLINE : Data from GlaxoSmithKline plc Provide New Insights into Bradyk..
04/20 GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc in the Area of Diphtheria Rep..
04/19 GLAXOSMITHKLINE : GSK makes change to financial reporting framework
More news
Sector news : Pharmaceuticals - NEC
04/22DJNovartis Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
04/19DJFARON PHARMACEUTICALS OY : Appoints Two Non-Executive Directors
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:27a 1st Quarter Portfolio Results - Better Than Expected
04/21 Teva Twin-Tracks Advair Competitor's Launch
04/21 EMA hands down a number of recommendations
04/21 Merck Leads Rivals In Novel Drug Approvals
04/20 What To Expect At GlaxoSmithKline's Q1/2017 Results
Advertisement
Financials ( GBP)
Sales 2017 30 027 M
EBIT 2017 8 303 M
Net income 2017 4 203 M
Debt 2017 14 127 M
Yield 2017 5,11%
P/E ratio 2017 19,45
P/E ratio 2018 16,57
EV / Sales 2017 3,03x
EV / Sales 2018 2,91x
Capitalization 76 980 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,8  GBP
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC0.22%98 598
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.88%200 330
NOVARTIS AG-1.15%192 857
MERCK & CO., INC.5.13%169 673
More Results